Figure 2
![Figure 2. Summary of the overall effects of particular second kinase inhibitors on the development and regression of BCR-ABL kinase domain mutations. After treatment with second TKI, 2 patients treated with nilotinib lost baseline mutations [(M35IT) and (G250E + F317L)] but acquired new mutations [(F359V) and (T315I + Y253H)], respectively; 1 patient treated with dasatinib lost baseline mutations (E459G + M351T + G250E) and acquired a new mutation (F317L). After treatment with a third TKI, 2 patients treated with dasatinib lost baseline mutations [(F311I + E453K) and (F359V)] but acquired new mutations [(F317L) and (V299L)], respectively.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/12/10.1182_blood-2007-03-080838/4/zh80010810660002.jpeg?Expires=1735591733&Signature=CXEAmvfLaxSrIySGLb7p~sgvGgPHzYOt45XdkUiedq0bPh2mz55YdwiyK-uS-frM0u59CAZVg2lVj6qwohVpIFYYGJFJDaRbnsxOpRJ-hBJFp7j-5L2~f4gNOK9g0GZG4n2lHzR1g4T~l415rQwmtTUvxTOLA7cun0TYnU-Aw~Ogvg4Vl3c6wWMPAxKXhzvFB3g3jjR63jtkG0Btrtxg0NUtVqUzdvQzTElBVyelEZpH1xval-nGrdWoPbWXIFEU0SI~8x-3Muq8RXsmO5byZ7C2EXAdujgWtYrLs5WGr60ZHaIO6D5FcrNp6IaBzEVs17PL0-7pI5--J~nk0dFfAw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Summary of the overall effects of particular second kinase inhibitors on the development and regression of BCR-ABL kinase domain mutations. After treatment with second TKI, 2 patients treated with nilotinib lost baseline mutations [(M35IT) and (G250E + F317L)] but acquired new mutations [(F359V) and (T315I + Y253H)], respectively; 1 patient treated with dasatinib lost baseline mutations (E459G + M351T + G250E) and acquired a new mutation (F317L). After treatment with a third TKI, 2 patients treated with dasatinib lost baseline mutations [(F311I + E453K) and (F359V)] but acquired new mutations [(F317L) and (V299L)], respectively.
